When radiation therapy saves lives from cancer, it can also leave behind a devastating legacy in healthy tissue. Radiation-induced brain necrosis—tissue death caused by previous radiotherapy—has long been one of oncology’s cruelest ironies: the treatment that eradicated a tumor slowly destroys surrounding neural structures months or even years later. A narrative review published June 2026 in Frontiers in Oncology offers a comprehensive synthesis of current therapeutic approaches, positioning hyperbaric oxygen therapy (HBOT) as a valuable intervention with documented efficacy in approximately 60% of affected patients.
The Hidden Cost of Curative Radiation
Radiation-induced brain necrosis (RIBN) represents the most severe form of radiation injury to the central nervous system. While modern techniques like stereotactic radiosurgery have improved targeting precision, the fundamental biological challenge remains: ionizing radiation damages vascular endothelium, triggers chronic inflammation, and creates a hypoxic environment that perpetuates tissue injury long after treatment completion.
The clinical presentation varies dramatically. Some patients develop progressive neurological deficits mimicking tumor recurrence. Others experience seizures, cognitive decline, or focal symptoms depending on the necrosis location. The diagnostic dilemma is profound: on standard MRI, radiation necrosis and recurrent tumor often appear virtually identical, requiring advanced imaging sequences or even biopsy for definitive differentiation.
What makes RIBN particularly challenging is its delayed onset. Symptoms typically emerge 6–24 months after radiotherapy, though cases have been reported decades later. This temporal disconnect often complicates recognition, with patients and physicians initially suspecting unrelated neurological conditions.
HBOT’s Mechanism in Radiation Injury
The biological rationale for HBOT in radiation injury rests on addressing the fundamental pathophysiology. Radiation damages small blood vessels, causing progressive narrowing, thrombosis, and eventual tissue hypoxia. This hypoxic state becomes self-perpetuating: poorly oxygenated tissue produces inflammatory cytokines and free radicals, causing further vascular damage and worsening hypoxia.
Hyperbaric oxygen therapy interrupts this cycle through several mechanisms. At pressures of 2.0–2.4 atmospheres absolute (ATA), plasma oxygen concentration increases dramatically—enough to support tissue metabolism independently of hemoglobin-bound oxygen. This super-oxygenation promotes angiogenesis, stimulating the growth of new capillaries to replace radiation-damaged vasculature. HBOT also reduces tissue edema, modulates inflammatory responses, and enhances fibroblast function necessary for tissue repair.
The 2026 Frontiers review emphasizes that these effects are particularly relevant to brain tissue, where the blood-brain barrier complicates drug delivery and the brain’s limited regenerative capacity makes vascular restoration critical for functional recovery.
Evidence Profile: What the Data Show
The Frontiers review, synthesizing multiple observational studies and case series, reports that HBOT stabilizes or improves symptoms in approximately 60% of patients with radiation necrosis. This figure represents pooled outcomes across heterogeneous populations, varying HBOT protocols, and different radiation injury severities—making it a conservative estimate rather than a definitive efficacy benchmark.
Response patterns typically follow a predictable trajectory. Neurological stabilization usually occurs during or immediately after the treatment course, while radiographic improvement on MRI may lag by weeks to months as neovascularization proceeds. Some patients demonstrate complete resolution of enhancing lesions; more commonly, HBOT halts progression and reduces edema, converting an active, destructive process into stable, quiescent scar tissue.
The review notes particular efficacy in patients treated earlier in the disease course, before extensive tissue destruction has occurred. This observation aligns with the broader hyperbaric medicine principle that radiation injury represents a progressively worsening process—intervention at earlier stages preserves more viable tissue and produces better functional outcomes.
FDA Position and Clinical Context
The U.S. Food and Drug Administration recognizes “late radiation tissue injury” as an approved indication for hyperbaric oxygen therapy. This classification encompasses radiation necrosis affecting various anatomical sites, including the brain. The FDA-cleared status distinguishes RIBN from the many unapproved wellness and longevity applications increasingly marketed to consumers.
However, the FDA emphasizes that HBOT is a medical procedure requiring physician oversight and appropriate patient selection. The 2025 FDA safety communication specifically warned against unsupervised use of hyperbaric chambers, highlighting fire risks and the potential for barotrauma and oxygen toxicity when protocols are not followed.
For patients with confirmed radiation necrosis, HBOT typically involves 30–40 sessions of 90–120 minutes each at 2.0–2.4 ATA. Treatment schedules vary by facility and severity, with some protocols using daily sessions five days weekly while others incorporate breaks to assess response. The time commitment is substantial—patients should understand that HBOT represents a significant investment of weeks to months.
Alternative and Adjunctive Approaches
The Frontiers review contextualizes HBOT within a broader therapeutic landscape. Corticosteroids remain first-line for acute symptom management, reducing vasogenic edema and providing temporary neurological improvement. However, steroids do not address underlying pathophysiology and carry significant long-term toxicity with extended use.
Bevacizumab, an anti-VEGF antibody, has demonstrated radiographic and clinical efficacy in randomized trials specifically for cerebral radiation necrosis. The review notes that bevacizumab and HBOT are not mutually exclusive—some treatment algorithms use HBOT for initial stabilization, reserving bevacizumab for refractory cases or combining modalities in severe presentations.
Surgical resection plays a role for large, mass-effect-producing lesions or when tissue diagnosis remains uncertain. However, operating within irradiated tissue carries elevated risks of poor wound healing and cerebrospinal fluid leak, precisely the complications HBOT is FDA-cleared to prevent in post-radiation surgical contexts.
Limitations and Uncertainties
The evidence base for HBOT in radiation necrosis, while positive, carries important caveats. The 60% response figure derives primarily from observational studies and case series rather than randomized controlled trials. No published RCT has specifically compared HBOT to placebo or standard care in isolated cerebral radiation necrosis, though such trials would face ethical and practical challenges given the condition’s severity and the established efficacy signals.
Patient selection significantly influences outcomes. The Frontiers review notes that smaller lesions, earlier intervention, and better baseline functional status predict treatment success. Conversely, extensive necrosis with significant mass effect or patients with poor performance status may have limited benefit despite HBOT.
The optimal treatment protocol—pressure, duration, number of sessions—remains incompletely defined. Current practice largely follows institutional experience and extrapolation from other radiation injury indications rather than prospective dose-finding studies.
Implications for Patients and Providers
For cancer survivors developing neurological symptoms months or years after radiotherapy, the possibility of radiation necrosis should prompt early referral to hyperbaric medicine specialists. The window for effective intervention may be narrower than commonly assumed; delaying HBOT until severe, irreversible tissue destruction has occurred limits therapeutic potential.
The 2026 Frontiers review reinforces a crucial message: radiation necrosis is not simply an unfortunate complication to be managed symptomatically, but an active pathological process amenable to disease-modifying therapy. HBOT offers a mechanism-directed approach that addresses hypoxia and vascular injury rather than merely masking symptoms.
Patients considering HBOT should seek treatment at UHMS-accredited facilities with experience in neurological indications. The technical demands of treating brain-injured patients—managing seizures, monitoring for cerebral edema during pressurization, coordinating with oncology teams—favor established hyperbaric centers over wellness-oriented operations lacking medical oversight.
As cancer survivorship grows and more patients live long enough to experience late radiation effects, the importance of effective RIBN management will only increase. The evidence synthesized in this review suggests that hyperbaric oxygen therapy, appropriately applied, can meaningfully alter the trajectory of this challenging condition for a substantial proportion of affected patients.